News headlines about Atrion (NASDAQ:ATRI) have been trending somewhat positive this week, according to Accern. The research group identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Atrion earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave media coverage about the medical instruments supplier an impact score of 45.9105275291596 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Separately, BidaskClub downgraded shares of Atrion from a “hold” rating to a “sell” rating in a research note on Tuesday, December 12th.
Shares of Atrion (NASDAQ:ATRI) opened at $594.95 on Friday. Atrion has a 12-month low of $454.10 and a 12-month high of $694.00. The stock has a market cap of $1,098.51, a price-to-earnings ratio of 32.96 and a beta of 0.85.
The business also recently disclosed a quarterly dividend, which was paid on Friday, December 15th. Stockholders of record on Friday, December 1st were given a dividend of $1.20 per share. This represents a $4.80 annualized dividend and a dividend yield of 0.81%. The ex-dividend date was Thursday, November 30th. Atrion’s dividend payout ratio is 26.59%.
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.